Intelligent bio solutions concludes in-clinic testing for clinical study plan, advancing toward fda 510(k) submission

New york, sept. 27, 2024 (globe newswire) -- intelligent bio solutions inc. (nasdaq: inbs) (“inbs” or the “company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of in-clinic testing proposed to the fda earlier this year in the company's clinical study plan.
INBS Ratings Summary
INBS Quant Ranking